AbbVie Inc. $ABBV Shares Sold by WealthPlan Investment Management LLC

Posted by Brian Himes on Oct 16th, 2026

WealthPlan Investment Management LLC lowered its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 6.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 44,522 shares of the company’s stock after selling 3,114 shares during the quarter. WealthPlan Investment Management LLC’s holdings in AbbVie were worth $11,647,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ABBV. Corient Private Wealth LP bought a new position in AbbVie during the second quarter worth about $559,736,000. Legal & General Group Plc purchased a new position in shares of AbbVie in the second quarter worth about $2,905,952,000. Jupiter Topco LLC purchased a new position in shares of AbbVie in the second quarter worth about $1,560,354,000. Diamant Asset Management Inc. raised its position in shares of AbbVie by 21,649.0% in the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock valued at $798,456,000 after purchasing an additional 3,654,351 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in shares of AbbVie in the second quarter valued at approximately $817,473,000. 70.23% of the stock is currently owned by institutional investors.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: New Phase 3 data for a subcutaneous version of SKYRIZI showed meaningful clinical and endoscopic benefits in adults with moderately to severely active Crohn’s disease. The results could support regulatory review of a more convenient induction option and strengthen confidence that SKYRIZI can help offset the loss of Humira revenue. Abbvie’s Crohn’s Disease Drug Skyrizi Shows More Positive Results
Positive Sentiment: Analyst sentiment remains constructive. Royal Bank of Canada reaffirmed an Outperform rating, while Erste Group raised its 2027 EPS estimate to $16.34 from $16.19 and maintained a Buy rating. These views reinforce the argument that AbbVie’s newer drugs are driving sustainable post-Humira growth. Royal Bank Of Canada Reaffirms Outperform Rating for AbbVie
Positive Sentiment: Investors are also watching early clinical work on oral candidate ABBV-1042. The study remains at an early stage and is being conducted in healthy participants, but positive progress could add value to AbbVie’s long-term pipeline. AbbVie’s ABBV-1042 Trial Update
Neutral Sentiment: AbbVie’s third-quarter earnings report is scheduled for October 30. Investors will be looking for confirmation that SKYRIZI and RINVOQ growth is more than compensating for Humira’s decline; the company’s current guidance calls for third-quarter EPS of $3.84 to $3.88. AbbVie’s Q3 2026 Earnings: What to Expect
Neutral Sentiment: Heavy call-option activity and a broad healthcare-sector rally indicate increased investor interest, but options positioning is not a fundamental catalyst by itself. Lower Treasury yields may also be supporting defensive healthcare shares.
Negative Sentiment: Some investors remain concerned that AbbVie’s valuation is demanding after its rally. Comparisons with Sanofi have highlighted Sanofi’s stronger outlook and valuation, potentially limiting further upside. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

AbbVie Stock Performance

Shares of ABBV opened at $283.07 on Friday. The stock’s 50-day simple moving average is $261.95 and its 200 day simple moving average is $238.90. The stock has a market capitalization of $500.13 billion, a price-to-earnings ratio of 79.96, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $291.40.

AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is presently 195.48%.

Analysts Set New Price Targets

ABBV has been the topic of a number of recent research reports. Guggenheim restated a “buy” rating and set a $288.00 price target on shares of AbbVie in a research note on Friday, October 9th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. BMO Capital Markets lifted their price objective on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Canaccord Genuity Group lifted their price objective on shares of AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $280.00 target price on shares of AbbVie in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $277.18.

Read Our Latest Stock Report on AbbVie

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

About AbbVie

(Free Report)

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.